Seizure in venlafaxine overdose: a 10-year retrospective review of the California poison control system

被引:4
作者
Vo, Kathy T. [1 ,2 ]
Merriman, Andrew J. [1 ]
Wang, Ralph C. [1 ]
机构
[1] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Calif Poison Control Syst, San Francisco Div, San Francisco, CA 94143 USA
关键词
Poison control centers; venlafaxine; seizure;
D O I
10.1080/15563650.2020.1712414
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Background: The optimal observation time period with respect to seizures after venlafaxine overdose is unclear. We conducted a 10-year retrospective review of calls to the California Poison Control System to describe the time of onset of seizures in adult and pediatric overdose of venlafaxine. Methods: Inclusion criteria included adult and pediatric patients with exposure to venlafaxine, who were admitted to a health care facility and who had at least one seizure. We did not exclude cases in which co-ingestions of other drugs were reported. Data extraction of a priori defined variables was recorded. Descriptive statistics were used to characterize the cohort of patients, including means, medians, and interquartile ranges. Results: The total number of cases included in the data analysis was 123 (12.9% of all venlafaxine ingestions). The longest time to last seizure was 24 h. Twenty-five percent of participants had a seizure from hour 7 to 24 h. This did not differ significantly between IR and XR formulations. Conclusions: Optimal observation time with respect to seizures after overdose of immediate-release formulation of venlafaxine is 18 h (24 h if ingested with other medications), and 21 h for patients who are poisoned with the sustained-release formulation.
引用
收藏
页码:984 / 990
页数:7
相关论文
共 16 条
[1]  
[Anonymous], VENL HYDR DRUG US ST
[2]  
Bourin M, 1999, ENCEPHALE, V25, P21
[3]  
Cheema N, 2014, CLIN TOXICOL, V52, P812
[4]   Understanding the limitations of retrospective analyses of poison center data [J].
Hoffinan, Robert S. .
CLINICAL TOXICOLOGY, 2007, 45 (08) :943-945
[5]  
Hoffman RS, 2005, AM FAM PHYSICIAN, V71, P43
[6]   The Effect of Decontamination Procedures on the Pharmacokinetics of Venlafaxine in Overdose [J].
Kumar, V. V. P. ;
Oscarsson, S. ;
Friberg, L. E. ;
Isbister, G. K. ;
Hackett, L. P. ;
Duffull, S. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) :403-410
[7]   Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis [J].
Lockhart, Pauline ;
Guthrie, Bruce .
BRITISH JOURNAL OF GENERAL PRACTICE, 2011, 61 (590) :e565-e572
[8]   The efficacy and safety of venlafaxine in the prophylaxis of migraine [J].
Ozyalcin, SN ;
Talu, GK ;
Kiziltan, E ;
Yucel, B ;
Ertas, M ;
Disci, R .
HEADACHE, 2005, 45 (02) :144-152
[9]   Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [J].
Rowbotham, MC ;
Goli, V ;
Kunz, NR ;
Lei, D .
PAIN, 2004, 110 (03) :697-706
[10]   Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats [J].
Santos, JG ;
Do Monte, FHM ;
Russi, M ;
Agustine, PE ;
Lanziotti, VMNB .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2002, 35 (04) :469-472